- ￥800 - 3250
- Solarbio|ActivAb
- 北京
- K011330M
- 2025年08月22日
- FCM
- Armenian Hamster
- Human;Rat;Mouse
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 亚型：
IgG
- 保存条件：
Store at 4℃ in dark.Do not freeze.
- 克隆性：
Monoclonal Antibody
- 标记物：
Biotin，Cy3，Cy3.5，Cy5，Cy5.5，Cy7，FITC，HRP，RBITC，Solar Fluor 350，Solar Fluor 405，Solar Fluor 488，Solar Fluor 532，Solar Fluor 555，Solar Fluor 568，Solar Fluor 594，Solar Fluor 633，Solar Fluor 640，Solar Fluor 647，Solar Fluor 660，Solar Fluor 680，Solar Fluor 750
- 适应物种：
Human;Rat;Mouse
- 目录编号：
29851
- 级别：
实验级别
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- 宿主：
Armenian Hamster
- 应用范围：
FCM
- 靶点：
CD278
- 抗体英文名：
Anti-CD278 (ICOS) Monoclonal Antibody
- 抗体名：
Activation inducible lymphocyte immunomediatory molecule; Activation-inducible lymphocyte immunomediatory molecule; AILIM; CD278; CD278 antigen; CVID1; ICOS; ICOS_HUMAN; Inducible costimulator; Inducible T cell co stimulator; Inducible T-cell costimulator
- 规格：
100ug/1mg
| 规格： | 100ug | 产品价格： | ￥800.0 |
|---|---|---|---|
| 规格： | 1mg | 产品价格： | ￥3250.0 |
| 基本信息 | |
| 英文名称 | Anti-CD278 (ICOS) Monoclonal Antibody |
| 宿主 | Armenian Hamster |
| 克隆类型 | Monoclonal Antibody |
| 亚型 | IgG |
| 交叉反应 | Human;Rat;Mouse |
| 应用 | FCM |
| 密度 | |
| 靶标 | CD278 |
| 别名 | Activation inducible lymphocyte immunomediatory molecule; Activation-inducible lymphocyte immunomediatory molecule; AILIM; CD278; CD278 antigen; CVID1; ICOS; ICOS_HUMAN; Inducible costimulator; Inducible T cell co stimulator; Inducible T-cell costimulator |
| 背景说明 | The protein encoded by this gene belongs to the CD28 and CTLA-4 cell-surface receptor family. It forms homodimers and plays an important role in cell-cell signaling，immune responses，and regulation of cell proliferation.[provided by RefSeq，Jul 2008]. |
| Swiss Prot | Q9Y6W8 |
| Gene ID | 29851 |
| 亚细胞定位 | Cell membrane |
| 储存条件 | Store at 4℃ in dark.Do not freeze. |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验The Application of Monoclonal Antibodies in the Treatment of Lymphoma
lymphoma treated with a chimeric anti-CD20 mAb, and Maloney and co-workers (2 ) recently reported a 50% response rate in relapsed, low-grade, NHL, with a 10---11 mo duration. Encouragingly, patients in these studies did not raise antibody responses
monoclonal antibodies have improved responses with minimal toxicities. For instance, Rituximab (chimeric anti-CD20 monoclonal antibody) was the first FDA-approved monoclonal antibody for the treatment of patients with non-Hodgkin’s lymphoma (NHL
Polyclonal and Monoclonal Antibodies
later again (2 + 2 week cycle). Monoclonal Antibody If titre is positive do one of the following 2 weeks later: I - Boost tail vein with 20 ug- 50 ug of Antigen in PBS and proceed with fusion on day 4. OR II - Boost
技术资料暂无技术资料 索取技术资料
